Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director · See Remarks | August 03, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 03, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 717,203 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 4,375 · Balance 717,203 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,410 F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,410 F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 124,956 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 124,956 F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 57,358 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 57,358 F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2023 Filed Dec 22, 2023 22:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 6,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000134 · wk-form4_1703283856.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 24,413 F1 · ownership.nature: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 6,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000134 · wk-form4_1703283856.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,019 Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 6,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000134 · wk-form4_1703283856.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,582 Read SEC document |
| December 01, 2023 Filed Dec 2, 2023 01:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 59,525 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-23-000129 · wk-form4_1701481885.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,823 Underlying: Common Stock · 59,525 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. F1 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 01, 2023 Filed Dec 2, 2023 01:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 59,525 | $1.68 | $100,037.72 |
DisclosureSEC source: 0001787306-23-000129 · wk-form4_1701481885.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| May 31, 2023 Filed Dec 2, 2023 01:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 1,463 | $6.38 | $9,333.94 |
DisclosureSEC source: 0001787306-23-000129 · wk-form4_1701481885.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,145 F2 · kind: Pursuant to the purchase transaction of the Company's Employee Stock Purchase plan. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,435 | $15.26 | $37,167.35 |
DisclosureSEC source: 0001567619-23-004672 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,657 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 69 | $16.52 | $1,139.88 |
DisclosureSEC source: 0001567619-23-004272 · doc1.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,092 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 5,403 | $15.82 | $85,465.73 |
DisclosureSEC source: 0001567619-23-004272 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,161 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Apr 1, 2023 01:54 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 232,000 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0001787306-23-000025 · wf-form4a_168031405519295.xml · derivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,000 Underlying: Common Stock · 232,000 shares Expires 2033-03-02 F3 · derivative.exercise_date: Amendment filed to add RSUs and Stock Options granted to Reporting Person on March 2, 2023. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Apr 1, 2023 01:54 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000025 · wf-form4a_168031405519295.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,592 F1 · shares: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, 25% of the RSUs vest annually on March 2 of each year, beginning on March 2, 2024, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Reflects amount of securities beneficially owned as of March 2, 2023. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,343 | $16.17 | $37,877.64 |
DisclosureSEC source: 0001567619-23-004272 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,564 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 00:09 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 100 | $17.03 | $1,703.00 |
DisclosureSEC source: 0001787306-23-000008 · wf-form4_167650612269186.xml · nonDerivative · entry 4 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 00:09 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 417 | $17.02 | $7,097.34 |
DisclosureSEC source: 0001787306-23-000008 · wf-form4_167650612269186.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:09 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 42 | $17.01 | $714.42 |
DisclosureSEC source: 0001787306-23-000008 · wf-form4_167650612269186.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:09 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 441 | $17.00 | $7,497.00 |
DisclosureSEC source: 0001787306-23-000008 · wf-form4_167650612269186.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,466 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:26 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 382 | $17.00 | $6,494.00 |
DisclosureSEC source: 0001787306-23-000006 · wf-form4_167545953621023.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:26 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 618 | $17.00 | $10,508.72 |
DisclosureSEC source: 0001787306-23-000006 · wf-form4_167545953621023.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,289 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $17.06 | $17,060.00 |
DisclosureSEC source: 0001787306-22-000079 · wf-form4_167062242477432.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:39 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $18.00 | $18,004.00 |
DisclosureSEC source: 0001787306-22-000073 · wf-form4_166802996099874.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.94 to $18.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 109,925 Restricted Stock Units. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 22:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $19.51 | $19,510.00 |
DisclosureSEC source: 0001567619-22-018418 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,907 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 21:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $21.51 | $21,510.00 |
DisclosureSEC source: 0001567619-22-017237 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,907 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F1 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-015354 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,348 Underlying: Common Stock · 2,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $24.74 | $61,858.00 |
DisclosureSEC source: 0001567619-22-015354 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,871 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $24.35 to $25.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,500 | $1.68 | $4,201.50 |
DisclosureSEC source: 0001567619-22-015354 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,087 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-013924 · doc1.xml · derivative · entry 9 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,848 Underlying: Common Stock · 7,087 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,087 | $25.41 | $180,111.85 |
DisclosureSEC source: 0001567619-22-013924 · doc1.xml · nonDerivative · entry 4 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,871 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $25.00 to $25.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 7,087 | $1.68 | $11,910.41 |
DisclosureSEC source: 0001567619-22-013924 · doc1.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,913 | $25.41 | $124,860.95 |
DisclosureSEC source: 0001567619-22-013924 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,871 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $25.00 to $25.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 23:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,500 | $25.00 | $37,500.00 |
DisclosureSEC source: 0001567619-22-013924 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,784 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 20:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $22.07 | $22,070.00 |
DisclosureSEC source: 0001567619-22-013783 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,284 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| June 23, 2022 Filed Sep 9, 2022 21:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 268,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-017237 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,907 F1 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| June 06, 2022 Filed Jun 6, 2022 20:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $21.06 | $21,064.00 |
DisclosureSEC source: 0001567619-22-012377 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,284 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.84 to $21.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Reflects the adjusted total which includes the purchase of 1,617 shares under the Arcutis Employee Stock Purchase Plan on May 31, 2022. F4 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| May 05, 2022 Filed May 5, 2022 21:31 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $21.76 | $21,760.00 |
DisclosureSEC source: 0001567619-22-009639 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,667 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 22:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $21.43 | $21,430.00 |
DisclosureSEC source: 0001567619-22-008131 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,667 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| March 09, 2022 Filed Mar 12, 2022 02:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 300 | $17.00 | $5,100.00 |
DisclosureSEC source: 0000899243-22-010801 · doc4.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,667 F1 · shares: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 109,925 restricted stock units "RSUs". The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 01:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-006498 · doc1.xml · derivative · entry 11 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,935 Underlying: Common Stock · 700 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F13 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 01:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 700 | $17.11 | $11,974.06 |
DisclosureSEC source: 0001567619-22-006498 · doc1.xml · nonDerivative · entry 5 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,967 F5 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $17.02 to $17.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F7 · balance_after: Includes 109,925 restricted stock units. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 01:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 700 | $1.68 | $1,176.42 |
DisclosureSEC source: 0001567619-22-006498 · doc1.xml · nonDerivative · entry 4 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 01:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 70 | $16.44 | $1,151.14 |
DisclosureSEC source: 0001567619-22-006498 · doc1.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,967 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F4 · price: The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 01:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,489 | $16.86 | $41,962.30 |
DisclosureSEC source: 0001567619-22-006498 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,037 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F3 · price: The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 188,100 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001567619-22-006498 · doc1.xml · derivative · entry 10 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,100 Underlying: Common Stock · 188,100 shares Expires 2032-03-03 F12 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 70,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006498 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663,526 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,153 | $17.75 | $38,221.56 |
DisclosureSEC source: 0001567619-22-006230 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592,626 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021. F2 · price: The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 47,200 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-003692 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,635 Underlying: Common Stock · 1,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $17.00 | $17,000.00 |
DisclosureSEC source: 0001567619-22-003692 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,000 | $1.68 | $1,680.60 |
DisclosureSEC source: 0001567619-22-003692 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-22-000851 · doc1.xml · derivative · entry 9 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,635 Underlying: Common Stock · 1,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 600 | $21.11 | $12,666.00 |
DisclosureSEC source: 0001567619-22-000851 · doc1.xml · nonDerivative · entry 4 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 100 | $22.06 | $2,206.00 |
DisclosureSEC source: 0001567619-22-000851 · doc1.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,379 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.